Publications by authors named "Jean-Louis David"
Objective: The purpose of this study was to define the prevalence and clinical characteristics of preeclampsia and eclampsia at a hospital in rural Haiti.
Methods: This is a retrospective review of women presenting to Hôpital Albert Schweitzer (HAS) in Deschapelles, Haiti with singleton pregnancy and diagnosis of preeclampsia or eclampsia from January 1, 2011 through December 31, 2012. Hospital charts were reviewed to obtain medical and prenatal history, hospital course, delivery information, and fetal/neonatal outcomes.
Article Synopsis
- Women in Haiti with preterm preeclampsia (PE) show a strong link between altered angiogenic factors and adverse maternal and fetal outcomes.
- Early onset PE (≤34 weeks) has a significantly higher rate of adverse outcomes compared to late onset PE (>34 weeks), with rates of 100% vs. 54.2% respectively.
- Plasma levels of antiangiogenic sFlt1 and proangiogenic PlGF are notably different in women with PE, indicating their potential role in predicting complications and outcomes in pregnancy.
Article Synopsis
- Ex vivo testing is crucial for identifying promising anticoagulant agents, with this study focusing on validating the thrombin generation assay for evaluating their effectiveness.
- Six anticoagulant drugs were tested using the Calibrated Automated Thrombogram (CAT) method to observe their effects on thrombin activity in healthy male volunteers, showing varying potency and mechanisms of action among the drugs.
- The CAT method proved to be a fast, reliable tool for screening these anticoagulants, offering advantages over traditional tests like the PT clotting assay by providing detailed insights into thrombin generation dynamics.
Platelet aggregation plays an important role in pathological situations such as myocardial infarction, unstable angina, peripheral artery disease, and stroke. Thus, pharmacological agents that specifically inhibit platelet aggregation are of great interest in the treatment and prevention of these cardiovascular diseases. Since binding of activated glycoprotein IIb/IIIa complex, a platelet surface integrin, to fibrinogen is the final step leading to platelet aggregation regardless of the initial stimulus, many researches have focused on the development of drugs that could antagonize this integrin.
View Article and Find Full Text PDFProstacyclin (PGI(2)) is a potent endogenous inhibitor of platelet function and possesses a strong vasodilator effect. Furthermore, prostacyclin is currently presented as the physiologic antagonist of thromboxane A(2)(TXA(2)), which exhibits pro-aggregatory and vasoconstrictor properties. So, the balance between PGI(2) and TXA(2) production is crucial for the cardiovascular system.
View Article and Find Full Text PDFArticle Synopsis
- Platelet aggregation is crucial in diseases like heart attacks and strokes, highlighting the need for effective antiplatelet therapies.
- Historically, aspirin has been the primary antiplatelet drug, but newer options including ADP receptor antagonists, phosphodiesterase inhibitors, and GP IIb/IIIa receptor antagonists have emerged.
- This review focuses on the recent developments in these antiplatelet agents, particularly their chemical properties and potential clinical applications.